FDA fines Globus Medical and CEO $1M for selling “rejected” bone graft products

FDA fines Globus Medical and CEO $1M for selling rejected bone graft products (MassDevice)

Orthopedics device maker Globus Medical and its CEO agree to pay a $1 million fine after an FDA inspection finds the company marketing bone graft products that the agency had denied for the U.S. market.

Orthopedics device maker Globus Medical will pay $1 million, including a fine for its chief officer, to settle FDA charges that the company marketed bone graft products without getting the agency's approval. The fine includes $550,000 in penalties and a $450,000 charge for Globus CEO David Paul. "Firm...


Unlock the full article and exclusive OrthoStreams insights: in-depth analyses, hot startups, trends, market intel, and Daily Newsletter—for just $1/day.
Subscribe Now—Up your Game !
 

Scroll to Top